Introduction: Gaining a higher response rate (RR) has usually been determined as a primary
end point in phase II trials evaluating the efficacy of new molecular targeted drugs. However …

Objectives As the bioavailability of erlotinib is dependent on gastric pH, an increase in
gastric pH via the concurrent use of gastric acid suppressive medications (AS) may reduce …

Background Through activation of adrenergic receptors, chronic stress can trigger the
secretion of neurotransmitters and hormones that enhance tumor growth, increase …

Purpose Although activating mutations in the epidermal growth factor receptor (EGFR) gene
are predictive markers for response to EGFR inhibitors, 30–40% of EGFR-mutant non-small …

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) represented by
gefitinib and erlotinib are widely used in treating non-small cell lung cancer (NSCLC) …

Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …

Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab
demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor …

We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor
(EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine …

Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …

Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …